Kymera Therapeutics (KYMR) Profit After Tax (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Profit After Tax data on file, last reported at -$69.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 5.57% year-over-year to -$69.2 million in Q1 2026; TTM through Mar 2026 was -$316.8 million, a 33.56% decrease from a year earlier, with the FY2025 full-year figure at -$311.4 million, down 39.08% from the prior year.
• Profit After Tax for Q1 2026 stood at -$69.2 million, up from -$90.0 million in the prior quarter.
• Over the last five years, Profit After Tax for KYMR reached as high as -$14.4 million in Q4 2023 and fell as low as -$90.0 million in Q4 2025.
• Historically, Profit After Tax has averaged -$52.8 million across 5 years, with a median of -$48.6 million in 2024.
• Across the five-year window, Profit After Tax jumped 51.48% in 2023 and sank 392.43% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$29.6 million in 2022, then soared by 51.48% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then declined by 27.16% to -$90.0 million in 2025, then grew by 23.05% to -$69.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$69.2 million in Q1 2026, -$90.0 million in Q4 2025, and -$81.0 million in Q3 2025.